SCOPUS 정보 검색 플랫폼

The Lancet

Volumn 377, Issue 9767, 2011, Pages 693-694

BLISS! Lupus learns its lessons

(1) Stone, John H a

a HARVARD MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BELIMUMAB; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

CLINICAL PRACTICE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLOMERULONEPHRITIS; HUMAN; NOTE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79952070018 PISSN: 01406736 EISSN: None Source Type: Journal
DOI: 10.1016/S0140-6736(10)61546-2 Document Type: Note

Times cited : (6)

References (6)

1
- 79952070370
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial
- for the BLISS-52 Study Group published online Feb 7. DOI:10.1016/S0140- 6736(10)61354-2
- Navarra SV, Guzmán RM, Gallacher AE, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; published online Feb 7. DOI:10.1016/S0140-6736(10)61354-2.
- (2011) Lancet
- Navarra, S.V.¹ Guzmán, R.M.² Gallacher, A.E.³

2
- 69749120918
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
- Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-78.
- (2009) Arthritis Rheum , vol.61 , pp. 1168-1178
- Wallace, D.J.¹ Stohl, W.² Furie, R.A.³

3
- 79952067962
- US Department of Health and Human Services June, (accessed Oct 21, 2010)
- US Department of Health and Human Services. Guidance for industry. Systemic lupus erythematosus - developing medical products for treatment. June, 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf (accessed Oct 21, 2010).
- (2010) Guidance for Industry. Systemic Lupus Erythematosus - Developing Medical Products for Treatment

4
- 28944445445
- Combined oral contraceptives in women with systemic lupus erythematosus
- DOI 10.1056/NEJMoa051135
- Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-58. (Pubitemid 41785892)
- (2005) New England Journal of Medicine , vol.353 , Issue.24 , pp. 2550-2558
- Petri, M.¹ Kim, M.Y.² Kalunian, K.C.³ Grossman, J.⁴ Hahn, B.H.⁵ Sammaritano, L.R.⁶ Lockshin, M.⁷ Merrill, J.T.⁸ Belmont, H.M.⁹ Askanase, A.D.¹⁰ McCune, W.J.¹¹ Hearth-Holmes, M.¹² Dooley, M.A.¹³ Von, F.J.¹⁴ Friedman, A.¹⁵ Tan, M.¹⁶ Davis, J.¹⁷ Cronin, M.¹⁸ Diamond, B.¹⁹ Mackay, M.²⁰ more..

5
- 69749096135
- Novel evidence-based systemic lupus erythematosus responder index
- Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143-51.
- (2009) Arthritis Rheum , vol.61 , pp. 1143-1151
- Furie, R.A.¹ Petri, M.A.² Wallace, D.J.³

6
- 0027325557
- The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
- Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-58. (Pubitemid 23223653)
- (1993) Quarterly Journal of Medicine , vol.86 , Issue.7 , pp. 447-458
- Hay, E.M.¹ Bacon, P.A.² Gordon, C.³ Isenberg, D.A.⁴ Maddison, P.⁵ Snaith, M.L.⁶ Symmons, D.P.M.⁷ Viner, N.⁸ Zoma, A.⁹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.